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Intraluminal release of 6-keto-PGF,, and TxBz in ex viva canine arteries and veins was assessed 
during five consecutive 1%min periods using static incubation and physiologic perfusion techniques. 
Arterial segments were perfused with 90 ml/min pulsatile tlow at 100 mm Hg and vein segments with 
90 ml/min nonpulsatile flow at 7 mm Hg. During the final 15-min period vessels were stimulated with 
arachidonic acid (AAS). Perfusion of vein segments caused a higher release of 6-keto-PGF,, during the 
first 30 min (P < 0.05) and following AAS (P < 0.05) than did static incubation. Perfused arterial 
segments exhibited a higher release than did incubated segments of 6-keto-PGF,, for 45 min (P < 0.0 1) 
as well as following AAS (P < 0.0 1). TxBr release was higher during the entire observation period in 
perfused arteries and veins compared to incubated vessels (P < 0.01 and < 0.05, respectively). There 
was no correlation between the amounts of 6-keto-PGF,, or TxBz released when comparing values 
obtained by one technique to values obtained by the other (P > 0.1). These data suggest that flow 
related shear stress alters vascular prostanoid production, and that such should be accounted for when 
interpreting results of studies on prostacyclin and thromboxane release from intact vessels. o 1988 
Academic Press, Inc 
INTRODUCTION 
Vascular wall prostanoid production is 
complex. Many factors are known to stimu- 
late prostanoid production from endothelial 
cells, including trauma [I], ischemia [2], im- 
munologic injury with complement activa- 
tion [3], irradiation [4-61, chemical factors 
[7-91, and platelet activation [lo]. Prostacy- 
clin, a potent vasodilator and inhibitor of 
platelet aggregation, is produced primarily 
by endothelium. It appears to have its domi- 
nant action locally, inasmuch as measured 
plasma levels of prostacyclin are too low to 
inhibit platelet aggregation or cause vasodi- 
lation [I 1, 121. Thromboxane, a potent 
platelet aggregator and vasoconstrictor, is 
produced predominantly by platelets, with 
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lesser amounts derived from endothelial 
cells. 
Earlier investigations on prostanoid gener- 
ating capacity of the vessel wall often yielded 
inconsistent results. In part, this was a reflec- 
tion of differing techniques used in assays, 
such as use of incubation of vessel homoge- 
nates [ 13- 151, whole vessels [ 161, endothelial 
surfaces [17], cultured endothelial cells [9, 
181, as well as use of incubation or flow de- 
vices [ 10, 19-2 11. There are few comparative 
studies of the different methods to assess 
prostanoid release. Data obtained by one 
method cannot be compared with data ob- 
tained by a different method. For example, 
in one study incubation of the whole vessel 
in comparison to perfusion of the lumen re- 
sulted in a higher release of prostacyclin and 
thromboxane, as well as a higher prostacy- 
clin:thromboxane ratio [20], with no consis- 
tent correlation in prostanoid release occur- 
ring between these two methods [22]. In 
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contrast, perfusion of cultured endothelial 
cells causes a higher release of prostacyclin 
than does static incubation [23]. In this re- 
gard most perfusion studies have utilized low 
volume flow and low pressure systems which 
do not reflect in viva flow conditions. The 
objective of this investigation was to com- 
pare in vitro release of prostacyclin and 
thromboxane from artery and vein segments 
subjected to physiologic pressure and flow 
versus that following static incubation. 
MATERIALS AND METHODS 
Arteries and veins were obtained from 16 
mongrel dogs. All studies were carried out in 
accordance with the “Principles of Labora- 
tory Animal Care” and “Guide for the Care 
of and Use of Laboratory Animals” (NIH 
Publication No. 80-23, revised 1978). 
Vessel harvest. Animals were anesthetized 
with pentobarbital (20 mg/kg), intubated, 
and mechanically ventilated. The external 
jugular veins or common carotid arteries 
were exposed through a midline anterior 
neck incision, and carefully dissected from 
surrounding tissues, with ligation of all 
branches. Vessels were then excised, follow- 
ing which they were rinsed and flushed with 
calcium and magnesium free Hanks’ bal- 
anced salt solution (HBSS-CMF) at 20°C 
(GIBCO Laboratories, Grand Island, NY; 
pH 7.4, 290 mOsm). Excised veins con- 
tracted to approximately half of their in situ 
length and arteries to two-thirds of their orig- 
inal length. Each vessel was divided into two 
pieces of equal length (approximately 3 cm 
for veins and 2.5 cm for arteries). These seg- 
ments were briefly stored in HBSS-CMF 
until being simultaneously mounted and ex- 
tended to their original in situ length in a 
perfusion system. 
Vessel perfutsion. Half the artery and vein 
segments were perfused with 25 ml of Hanks’ 
balanced salt solution (GIBCO Laboratories, 
pH 7.4,290 mOsm) at 37°C for five 15-min 
periods. The perfusate was collected after 
each study period and stored at -70°C for 
subsequent prostanoid radioimmunoassay 
(RIA). Arachidonic acid (AA) was added to 
the final 15-min perfusate, providing a con- 
centration of 4 pg/ml. In order to simulate 
normal in vivo perfusion patterns, vein seg- 
ments were perfused at 7 mm Hg pressure 
with nonpulsatile flow of 90 ml/min, and ar- 
terial segments were perfused at 100 mm Hg 
pressure with pulsatile flow of 90 ml/min. 
The exact length and luminal circumference 
of the vessels being tested were measured and 
the luminal surface area exposed to the per- 
fusate was calculated. 
Vessei incubation. The remaining half of 
the artery and vein segments were mounted 
in the perfusion system as noted above, but 
they were not perfused. In order to create a 
pressure of approximately 7 mm Hg inside 
the segments, the system was filled with 5 ml 
of HBSS with an attached column filled to 10 
cm height. At the end of each 15-min study 
period, the incubate, including the fluid col- 
umn, was slowly propagated forward to 
allow all the HBSS containing 6-keto-PGF,, 
and TxB2 to be collected. The final incubate 
had AA added, to provide a concentration of 
4 pg/ml. As was the case with the flow stud- 
ies, the incubate medium was collected and 
stored at -70°C for later prostanoid RIA. 
Luminal surface area exposed to the incu- 
bate was calculated as described above. 
Vessel preparation for microscopy. Speci- 
mens were prepared for scanning electron 
microscopy following perfusion or incuba- 
tion by pressure fixation in 2.5% glutaralde- 
hyde in 0.1 M cacodylate buffer (veins at 7 
mm Hg, arteries at 100 mm Hg). Vessel seg- 
ments were then dehydrated in ethanol, in- 
cubated for 10 min in hexamethydisilazane 
(HMDS), dried in air, and sputter coated 
with gold-palladium [24]. 
Prostacyclin and thromboxane assays. 
Prostanoids were extracted from the HBSS 
according to a modification of the method 
described by Simmons [25]. Briefly, acetoni- 
trile was added to the perfusate solution to 
precipitate proteins which were then dis- 
carded. The supernatant was acidified with 
formic acid and mixed with ether to remove 
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the lipids, from which the prostaglandins 
were extracted three times into ethyl acetate, 
dried in air, and then redissolved in 0.1% 
porcine skin-gel-phosphate-buffered saline. 
All studies were performed in duplicate. 
Prostacyclin was measured as its stable 
degradation product 6-keto-PGF,, using a 
commercial radioimmunoassay kit (New 
England Nuclear, Boston, MA). This 
method employed an overnight incubation 
of 3H-labeled 6-keto-PGF,, and a test sample 
with a constant amount of specific antibody 
raised against a BSA conjugate. The bound 
6-keto-PGFr, was absorbed with an acti- 
vated charcoal suspension. The supematant 
was then subjected to liquid scintillation with 
quantitation of fl activity. These values were 
compared with those from freshly made 
standard dilutions of 6-keto-PGF,, . The 
amounts of 6-keto-PGFr, in the test sample 
were calculated by RIANAL computer anal- 
ysis. The cross reactivity for other prosta- 
glandins using this assay was: PGF, = 2.5%, 
PGF,, = 0.3%, PGE, = 0.2%, PGF*, 
= 0.05%, and TxB2 < 0.3%. 
Thromboxane was measured as its stable 
degradation product TxB2 according to a ra- 
dioimmunoassay similar to that described 
above, also using 3H-labeled tracer as noted 
previously [26]. The cross-reactivity with 
other prostaglandins using this particular 
assay was PGD2 = l.O%, PGD, = 0.32%, 
PGF,, = 0.04%, and PGF2, = 0.04% [26]. 
Prostanoid generation in this work is ex- 
pressed as pg/mm’ luminal area/l 5 min. 
Statistical significance of differences in pros- 
tanoid data was assessed using the Wilcoxon 
signed rank test. 
RESULTS 
Arteries. Incubation in arteries was asso- 
ciated with an initial burst release of 6-keto- 
PGF,, followed by a rapid decline after 30 
min (Fig. 1) to approximately a third of the 
initial value (P < 0.01). 6-keto-PGF,, release 
then remained stable for 60 min. With AA 
stimulation (AAS), there was a 2.2-fold in- 
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FIG. 1. Intraluminal release of 6-keto-PGF,, in arter- 
ies: Effect of physiologic flow and pressure (P = 100 mm 
Hg, Q = 90 ml/min, pulsatile) and static incubation (P 
= 7 mm Hg, Q = no flow). 
hand, caused a 20-fold increase in 6-keto- 
PGF,, release during the first 15 min in con- 
trast to later periods of perfusion (P c 0.01). 
Comparison of the two techniques revealed 
nearly an S-fold higher initial release of 6- 
keto-PGF,, with perfusion (P < 0.01). Al- 
though this difference diminished with time, 
it remained significant at 45 min (P c 0.01). 
However, at 60 min, release was the same 
regardless of which method was used (P 
= 0.2). With AAS in incubated arteries, re- 
lease of 6-keto-PGF,, increased approxi- 
mately 2-fold, whereas in perfused segments 
release increased approximately 8-fold, a dif- 
ference between the two techniques that was 
statistically significant (P < 0.0 1). 
Release of TxB2 from incubated arteries 
(Fig. 2) paralleled the pattern of 6-keto- 
PGFr, release, although such occurred at 
much lower levels. This resulted in a rela- 
tively constant prostacyclin to thromboxane 
(PT) ratio during the early observation pe- 
riods. Release of TxB2 from perfused seg- 
ments declined with time but was less than 
the decrease in 6-keto-PGF,,, which led to a 
decreased P:T ratio at 45 and 60 min. AAS 
caused the P:T ratio to increase to its initial 
level (P < 0.01). TxBz release was signifi- 
cantly greater from perfused segments than 
from incubated segments during the entire 
study (P < 0.01). This led to a slightly lower 
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FIG. 2. Intraluminal release of TxBz in arteries: Effect 
of physiologic flow and pressure (P = 100 mm Hg, Q 
= 90 ml/min, pulsatile) and static incubation (P = 7 mm 
Hg, Q = no flow). 
P:T ratio in perfused arteries when compared 
to incubated arteries, although such was sta- 
tistically significant only after AAS (P 
< 0.01). 
Veins. Static incubation of veins caused an 
immediate burst release of 6-keto-PGF,, 
which decreased to two-thirds of the initial 
value after 15 min (P < 0.05), and remained 
relatively stable until 60 min, at which time 
AAS caused a 2.6-fold increase (Fig. 3). Per- 
fusion of veins also caused an initial burst 
release of 6-keto-PGF,,, with an &fold 
higher release during the first 15 min than at 
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FIG. 3. I&alumina1 release of 6-keto-EGF,, in veins: FIG. 4. Intraluminal release of TxBr in veins: Effect of 
Effect of physiologic flow and pressure (P = 7 mm Hg, Q physiologic flow and pressure (P = 7 mm Hg, Q = 90 
= 90 ml/min, nonpulsatile) and static incubation (P = 7 ml/min, nonpulsatile) and static incubation (P = 7 mm 
mm Hg, Q = no now). Hg, Q = no flow). 
AAS of perfused veins produced an increase 
in 6-keto-PGF,, (P < O.OOS), to a level simi- 
lar to that of the initial burst. Comparison of 
perfused versus incubated segments revealed 
a higher release from perfused vein segments 
for 30 min (P < 0.05) and following AAS (P 
< 0.05). 
TxB2 release from incubated veins rapidly 
declined and remained stable after the first 
15-min burst (Fig. 4). In contrast to 6-keto- 
PGF,,, AAS failed to increase TxB2 release 
from incubated veins. Perfusion caused an 
initial burst release of TxB2 which decreased 
to about an eighth of the initial value by 60 
min (P < 0.005). AAS of perfused veins in- 
creased TxB2 release 2-fold (P < 0.0 1). TxBz 
release was higher from perfused veins com- 
pared to incubated veins throughout the en- 
tire observation period (P < 0.05). 
The P:T ratio from incubated veins was 
relatively stable during the study but did tend 
to be higher with AAS (P < 0.1). The P:T 
ratio from perfused veins was also stable for 
60 min, but with AAS was significantly in- 
creased (P < 0.01). The P:T ratio was not 
statistically different between incubated and 
perfused vein segments (P > 0.1). 
Attempts to relate quantities of 6-keto- 
PGF,, generated from incubation to quanti- 
ties generated from perfusion did not reveal 
any correlation for release from either arter- 
q Perfusad 
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ies (Y = 0.65, P = 0.08) or veins (r = 0.44, P 
= 0.2). Similarly, no correlation existed in 
TxB2 values when comparing data from in- 
cubation to perfusion methods in either ar- 
teries (I < 0.6, P > 0.1) or veins (r < 0.5, P 
> 0.2). 
More than 90% of the luminal surfaces of 
both artery and vein specimens after 75 min 
of incubation or perfusion was covered with 
endothelial cells. No relation was found be- 
tween differences in endothelial coverage 
and the amount of prostacyclin or throm- 
boxane released. Solitary platelets were occa- 
sionally found along the surface, but there 
were no platelet aggregates observed in these 
vessels. 
DISCUSSION 
In determining the capacity of arteries and 
veins to release prostacyclin and thrombox- 
ane, it seems appropriate to use a technique 
that gives a maximal stimulation of the ves- 
sels without impairing their ability to pro- 
duce prostanoids. Such a method should im- 
itate events that occur in viva. This current 
study clearly documents that veins and arter- 
ies subjected to physiologic pressure and flow 
conditions release higher amounts of prosta- 
cyclin and thromboxane than when exposed 
to conditions of static incubation. The higher 
initial release during the first 15-min period 
might reflect release due to vessel manipula- 
tion during dissection, instrumentation, and 
cannulation. The fact that prostacyclin and 
thromboxane release was greater with perfu- 
sion than incubation, as well as with AAS 
supports the contention that this experimen- 
tal model allows study of stimulated pros- 
tanoid release from arteries and veins. 
Higher release of prostanoids from per- 
fused vessels compared to incubated vessels 
may be explained in part by a number of 
factors. First, as proposed by Grabowski and 
colleagues [ 171, prostacyclin and thrombox- 
ane might be mixed more with the entire 
quantity of solution when perfused instead of 
staying in high concentrations at the inter- 
face of the endothelial cells with static incu- 
bation fluids. High concentrations at this in- 
terface may have an inhibitory effect on 
prostanoid release. A second factor relates to 
shear stress. Cultured endothelial cells ex- 
posed to increased shear stress are known to 
increase prostacyclin release [23, 271. In the 
former studies the higher release was evident 
only during the first few minutes of increased 
shear stress, whereas in the present study a 
continuous increase was noted over the first 
30 min. This discrepancy may be related to 
differences in endothelial cells in culture 
compared to those in intact vessels, or to the 
pulsatile nature of flow with variable shear in 
the arterial segments. Shear stress appears to 
enhance prostanoid release, perhaps by me- 
chanical stimulation, with increased phos- 
pholipid substrate or accelerated phospholi- 
pase or cyclooxygenase activity. In a pre- 
viously published study from our laboratory, 
increases in pressure up to 100 mm Hg en- 
hanced initial release of prostacyclin in 
veins, but caused impaired responses to AAS 
[28]. In the current investigation the vein 
pressure was kept constant for both perfu- 
sion and incubation. Variables included a 
lesser amount of solution in direct contact 
with the vessel during incubation studies and 
the presence of flow in perfusion studies. In 
arterial studies, there was addition of pres- 
sure, flow, and pulsatility with perfusion. 
The decline in prostanoid release over 
time in our studies may be speculated to be 
an effect of an accommodation of cells to 
new stimuli; a lack of phospholipids or an 
inhibition of phospholipid release leading to 
a lack of AA substrate; or an inhibition of 
cyclooxygenase activity. A loss of endothe- 
lium might also be implicated in that the 
presence of endothelial cells has been shown 
to be of importance for the response to ex- 
ternally provided AA [ 10, 29, 301. However, 
over 90% of the vessel’s endothelium re- 
mained intact in both perfused and incu- 
bated conduits. Therefore, the diminished 
prostanoid release with time is not due to loss 
of endothelial cells. Furthermore, the lack of 
platelets in both incubated and perfused seg- 
ments excludes them as a source of TxB2. 
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Prostacyclin release data from perfused ar- 
teries in the current experiment should not 
be rigidly compared to data from perfused 
veins. First, the segments were from different 
animals. Second, arterial segments in this 
particular study were from animals subjected 
to vein harvest for a different experiment, 
hours earlier. Third, they were perfused at 
different pressures. Fourth, arteries were per- 
fused with a pulsatile flow whereas veins 
were perfused with a nonpulsatile flow. Fifth, 
the samples were run in separate RIA assays. 
However, the observed differences in prosta- 
cyclin release between arteries and veins in 
this study are consistent with those reported 
by others [ 13, 221. The overwhelming con- 
clusion from reviewing existing data is that 
arteries respond with a higher release of 
prostacyclin compared to veins when ex- 
posed to physiological pressure and flow pat- 
terns, as well as when subjected to identical 
physical stresses. 
Externally provided AA in the current ex- 
periment caused veins to release 6-keto- 
PGFr, at the same level as during their initial 
perfusion. This is in contrast to arteries, 
which with AAS released about a third of 
their initial burst level. One explanation for 
this discrepancy might be that arteries pos- 
sess more substrate than veins, but exhibit a 
more pronounced inhibition of cyclooxy- 
genase or prostacyclin synthetase than do 
veins. A second explanation may be that ar- 
teries removed for study 3 hr after an earlier 
vein harvest were stimulated in vivo, possibly 
by thrombin [8]. A third explanation relates 
to the possibility that the initial burst consists 
of prostacyclin from two different sources, of 
which only one responded to later AAS. Two 
such sources are endothelial cells and 
smooth muscle cells, the former responding 
to AAS with a 20-fold greater release of pros- 
tacyclin [ 10, 29, 3 I]. 
Greater release of both prostacyclin and 
thromboxane when perfused ex vivo com- 
pared to static incubation, only allows one to 
estimate the general responsiveness of ves- 
sels. Extrapolation of in vitro results to in 
vivo events must be undertaken cautiously, 
inasmuch as other factors probably affect 
prostaglandin synthesis, some of which un- 
doubtedly have greater influence than those 
studied in this current experiment. 
The more pronounced response to physio- 
logic perfusion, together with the reproduc- 
ible pattern of prostanoid release over time, 
causes us to favor the perfusion technique 
over the static incubation technique when 
assessing the luminal release of prostacyclin 
and thromboxane. The poor correlation be- 
tween these two methods suggests that dif- 
ferent regulatory mechanisms exist when 
vessels are perfused compared to when they 
are subjected to static incubation. 
Certain conclusions should be apparent 
from this investigation. First, although sta- 
tistically significant differences in prostanoid 
production of several magnitudes existed 
with incubation assays, the absolute amounts 
involved may not approach the quantities of 
prostaglandins released under physiologic 
conditions. As such, these differences are of 
limited relevance in understanding normal 
or abnormal vessel wall physiology. Second, 
because of the exceedingly disparate results 
of the methods studied, one must use great 
caution in interpreting previously reported 
prostanoid release data, especially those de- 
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